PuraMed BioScience Engages Cannella Response Television Inc.

SCHOFIELD, Wis., May 18, 2009 (GLOBE NEWSWIRE) -- PuraMed BioScience, Inc.
(OTCBB:PMBS), a pharmaceutical company engaged in the development and marketing
of a line of revolutionary, new, non-prescription medicines targeting major
consumer health needs including the treatment of migraine headaches, insomnia
and tension-type headaches, announced today that they have engaged Cannella
Response Television (CRT). This is the first step in the execution of their
initial go-to market strategy, which will utilize the power of a direct response
television commercial to inform and educate the U.S. consumer of our
organization and our powerful LipGesic M product for the relief of migraine
headaches.

Cannella Response Television (http://www.drtv.com), headquartered in Burlington
WI, with offices in New York and Los Angeles, specializes in television direct
response media placement on national cable networks and broadcast stations. In
an industry that has its share of "One-Hit Wonders," Frank Cannella (Chairman
and Founder) has been in business for almost 25 years and has assembled a team
that has over 75 years of Direct Response Television experience. The company has
placed media for many of the industry's biggest hits and often supplements media
to other agencies.

The company's primary motivation in engaging Cannella hinges on their vast
breadth and depth of direct response industry knowledge. Cannella is unique in
that it goes beyond the typical media placement services by adding value through
a broad range of consulting services. Cannella works with clients as a project
manager to guide them through the infomercial process, lending expertise to such
areas as product assessment, script analysis, rough-cut evaluation,
telemarketing scripting and fulfillment recommendations.

In response to this agreement, Russ Mitchell, CEO, said, "We feel fortunate to
have secured an agreement with a company that can assist in the overall
management of our campaign. CRT can provide the guidance necessary to make a
positive difference in the execution of our Direct Response Television
initiative."

In other news, PuraMed BioScience Inc. will be publishing an article on Monday,
5/18/2009, in the Wall Street Journal and the Investors Business Daily. There
will be a series of articles over the next 8 weeks that are designed to educate
the U.S. consumer about our company and our product offering.

This news release contains forward-looking statements regarding PuraMed
BioScience and its future business plans, which statements involve known and
unknown risks and uncertainties. Such risks and uncertainties may cause actual
results and future achievements of PuraMed BioScience to be materially different
than those implied by these forward-looking statements. PuraMed BioScience has
and undertakes no obligation to provide public updates and revisions to these
forward-looking statements to reflect any changes in its expectations of future
events.

The PuraMed BioScience Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6155

-0-
CONTACT: PuraMed BioScience, Inc.
Russell Mitchell, CEO
715.359.6373
Info@puramedbioscience.com
http://www.puramedbioscience.com